Literature DB >> 24187444

Hepatitis C, stigma and cure.

Rui Tato Marinho1, David Pires Barreira.   

Abstract

The infection with hepatitis C virus (HCV) is one of the most important global chronic viral infections worldwide. It is estimated to affect around 3% of the world population, about 170-200 million people. Great part of the infections are asymptomatic, the patient can be a chronic carrier for decades without knowing it. The most severe consequences of the chronic infection are liver cirrhosis and hepatocellular carcinoma, which appears in 20%-40% of the patients, leading to hepatic failure and death. The HCV was discovered 25 years ago in 1989, is a RNA virus and classified by the World Health Organization as an oncogenic one. Hepatocellular carcinoma is one of the most important cancers, the fifth worldwide in terms of mortality. It has been increasing in the Ocidental world, mainly due to chronic hepatitis C. Hepatitis C is not only a liver disease and a cause of cirrhosis, but also a mental, psychological, familiar, and social disease. The stigma that the infected person sometimes carries is tremendous having multiple consequences. The main cause is lack of adequate information, even in the health professionals setting. But, besides the "drama" of being infected, health professionals, family, society and the infected patients, must be aware of the chance of real cure and total and definitive elimination of the virus. The treatment for hepatitis C has begun in the last 80's with a percentage of cure of 6%. Step by step the efficacy of the therapy for hepatitis C is rapidly increasing and nowadays with the very new medications, the so called Direct Antiviral Agents-DAAs of new generation, is around 80%-90%.

Entities:  

Keywords:  Chronic; Depression; Hepatic cirrhosis; Hepatitis C; Hepatocellular carcinoma; Interferon-alpha; Ribavirin; Social stigma; Therapy

Mesh:

Substances:

Year:  2013        PMID: 24187444      PMCID: PMC3812468          DOI: 10.3748/wjg.v19.i40.6703

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  64 in total

1.  A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.

Authors:  Gregory T Everson; Norah A Terrault; Anna S Lok; Del R Rodrigo; Robert S Brown; Sammy Saab; Mitchell L Shiffman; Abdullah M S Al-Osaimi; Laura M Kulik; Brenda W Gillespie; James E Everhart
Journal:  Hepatology       Date:  2013-01-17       Impact factor: 17.425

2.  Purpura with cold urticaria in a patient with hepatitis C virus infection-associated mixed cryoglobulinemia type III: successful treatment with interferon-beta.

Authors:  Akiko Ito; Takashi Kazama; Kaoru Ito; Masaaki Ito
Journal:  J Dermatol       Date:  2003-04       Impact factor: 4.005

3.  Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.

Authors:  P Marcellin; N Boyer; A Gervais; M Martinot; M Pouteau; C Castelnau; A Kilani; J Areias; A Auperin; J P Benhamou; C Degott; S Erlinger
Journal:  Ann Intern Med       Date:  1997-11-15       Impact factor: 25.391

4.  Understanding social stigma in women with hepatitis C.

Authors:  Gillian Grundy; Nicholas Beeching
Journal:  Nurs Stand       Date:  2004 Oct 6-12

5.  Severe hepatitis C virus-related cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study.

Authors:  J Koskinas; C Kilidireas; N Karandreas; D Kountouras; S Savvas; E Hadziyannis; A J Archimandritis
Journal:  Liver Int       Date:  2007-04       Impact factor: 5.828

6.  Determining the extent of quality health care for hospitalized patients with cirrhosis.

Authors:  Jayant A Talwalkar
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

7.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

8.  The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.

Authors:  Roberta D'Ambrosio; Alessio Aghemo; Mirella Fraquelli; Maria Grazia Rumi; Maria Francesca Donato; Valerie Paradis; Pierre Bedossa; Massimo Colombo
Journal:  J Hepatol       Date:  2013-03-23       Impact factor: 25.083

9.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

10.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

View more
  34 in total

1.  Health-Related Quality of Life in Portuguese Patients with Chronic Hepatitis C.

Authors:  Andreia Rei; Marta Rocha; Isabel Pedroto
Journal:  GE Port J Gastroenterol       Date:  2016-12-03

2.  Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis.

Authors:  Nicolae-Catalin Mechie; Christian Röver; Silke Cameron; Ahmad Amanzada
Journal:  World J Hepatol       Date:  2014-10-27

3.  A Descriptive Analysis of a Community Clinic Providing Hepatitis C Treatment to Poor and Uninsured Patients.

Authors:  Omar T Sims; Pamela A Melton; Shaonin Ji
Journal:  J Community Health       Date:  2018-08

4.  Health-Related Quality of Life in Chronic Hepatitis C.

Authors:  Helder Cardoso; Marco Silva
Journal:  GE Port J Gastroenterol       Date:  2017-01-17

5.  "Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment.

Authors:  A W Batchelder; D Peyser; S Nahvi; J H Arnsten; A H Litwin
Journal:  Drug Alcohol Depend       Date:  2015-06-09       Impact factor: 4.492

6.  Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.

Authors:  X Li; N S Chan; A W Tam; I F N Hung; E W Chan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-17       Impact factor: 3.267

7.  Hepatitis B-related knowledge and vaccination in association with discrimination against Hepatitis B in rural China.

Authors:  Lijie Yu; Jian Wang; Dawei Zhu; Anli Leng; Knut R Wangen
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452

Review 8.  Virus-related liver cirrhosis: molecular basis and therapeutic options.

Authors:  Ji Lin; Jian-Feng Wu; Qi Zhang; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 9.  Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications.

Authors:  Peter Hauser; Shira Kern
Journal:  World J Hepatol       Date:  2015-07-28

Review 10.  Hepatitis C: Treatment of difficult to treat patients.

Authors:  Eric G Hilgenfeldt; Alex Schlachterman; Roberto J Firpi
Journal:  World J Hepatol       Date:  2015-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.